期刊
NATURE COMMUNICATIONS
卷 11, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41467-020-16969-0
关键词
-
资金
- BHF [PG/18/5033837]
- UCL BHF [AA/18/6/34223]
- National Institute for Health Research University College London Hospitals Biomedical Research Centre
- BHF Fellowship [FS/14/76/30933, FS/17/70/33482]
- UK Medical Research Council [FC001002, MR/N013867/1]
- BenevolentAI
- Rosetrees Trust
- Stoneygate Trust
- UCL Hospitals NIHR Biomedical Research Centre
- EU/EFPIA Innovative Medicines Initiative [2] Joint Undertaking BigData@Heart grant [116074]
Mendelian randomisation (MR) analysis is an important tool to elucidate the causal relevance of environmental and biological risk factors for disease. However, causal inference is undermined if genetic variants used to instrument a risk factor also influence alternative disease-pathways (horizontal pleiotropy). Here we report how the 'no horizontal pleiotropy assumption' is strengthened when proteins are the risk factors of interest. Proteins are typically the proximal effectors of biological processes encoded in the genome. Moreover, proteins are the targets of most medicines, so MR studies of drug targets are becoming a fundamental tool in drug development. To enable such studies, we introduce a mathematical framework that contrasts MR analysis of proteins with that of risk factors located more distally in the causal chain from gene to disease. We illustrate key model decisions and introduce an analytical framework for maximising power and evaluating the robustness of analyses. Mendelian randomisation (MR) analysis of drug targets has potential to aid drug development. Here, the authors introduce a mathematical framework to elucidate this specific application of MR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据